{
  "prompt": {
    "prompt": "Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\n\nFor each recommendation, specify:\n1. The type of recommendation:\n   - Additional information needed (history/examination/investigations)\n   - Improved patient advice (options/statistics/patient information)\n   - Different management plan\n2. The specific recommendation\n3. The reason for the recommendation (referencing the guideline)\n\nCategorize each recommendation by importance:\n- Very Important: Critical for patient safety or guideline compliance\n- Somewhat Important: Significant for optimal care but not critical\n- Less Important: Would improve care but not essential\n- Unimportant: Minor suggestions that could be considered\n\nFormat the response as follows:\n\n### Very Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Somewhat Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Less Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Unimportant Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\nClinical Note:\n**Dictation: Clinical Interaction – Multiple Gestation (Fictional for Testing Purposes Only)**  \n\n**Patient Name:** Sarah Thompson  \n**Age:** 32  \n**Gestational Age:** 24 weeks  \n**Gravidity/Parity:** G3 P1 (previous vaginal delivery at term)  \n**Weight:** 68 kg  \n**Last Menstrual Period:** Estimated based on early ultrasound  \n**Chief Complaint:** \"I’ve been having more frequent Braxton Hicks contractions and some lower back pain.\"  \n\n### **History of Present Illness:**  \nMs. Thompson is a 32-year-old woman with a dichorionic diamniotic twin pregnancy, confirmed by first-trimester ultrasound. She reports increased frequency of Braxton Hicks contractions over the past week, occurring 3–4 times per hour, non-painful but noticeable. She denies vaginal bleeding, fluid leakage, or decreased fetal movement. She notes intermittent lower back pain, which she attributes to prolonged standing at work. No recent travel or illness.  \n\n*Missing Pertinent Questions:*  \n- No documented inquiry about urinary symptoms (possible UTI contributing to contractions).  \n- No detailed dietary history (potential nutritional deficiencies in twin gestation).  \n- No assessment of recent stressors or sleep disturbances.  \n\n### **Past Medical/Surgical History:**  \n- Hypothyroidism (on levothyroxine, last TSH within normal range).  \n- No prior gestational diabetes or hypertension.  \n- No surgeries.  \n\n### **Medications:**  \n- Prenatal vitamins  \n- Levothyroxine 50 mcg daily  \n\n### **Family History:**  \n- Mother with type 2 diabetes.  \n- No known twin pregnancies in family.  \n\n### **Social History:**  \n- Works full-time as a teacher.  \n- No tobacco, alcohol, or recreational drug use.  \n- Married, supportive partner.  \n\n### **Review of Systems:**  \n- **Constitutional:** No fever, fatigue reported.  \n- **Cardiovascular:** No palpitations or edema.  \n- **Respiratory:** No shortness of breath.  \n- **Gastrointestinal:** Occasional heartburn, no nausea/vomiting.  \n- **Neurological:** No headaches or visual changes.  \n\n*Missing Pertinent Exam Findings:*  \n- No fundal height measurement documented.  \n- No cervical exam performed (to assess for shortening/dilation).  \n- No documentation of fetal heart tones for both twins.  \n\n### **Assessment:**  \n- **Multiple gestation (DCDA twins)** at 24 weeks with increased Braxton Hicks contractions.  \n- Differential includes normal uterine irritability vs. preterm labor risk.  \n- Back pain may be musculoskeletal but requires monitoring.  \n\n### **Plan:**  \n1. **Activity Modification:** Advised reduced standing, pelvic rest, and hydration.  \n2. **Contraction Monitoring:** Instructed to time contractions—if ≥6/hour or painful, present to labor and delivery.  \n3. **Nutrition:** Emphasized increased protein/caloric intake (not quantified).  \n4. **Follow-Up:** Scheduled for growth ultrasound in 2 weeks; no additional cervical length screening ordered.  \n5. **Patient Counseling:** Discussed signs of preterm labor but did not provide written materials.  \n\n*Gaps in Management:*  \n- No referral to maternal-fetal medicine despite twin gestation.  \n- No discussion of antenatal corticosteroids for fetal lung maturity in case of preterm delivery.  \n- No contingency plan if symptoms worsen before next visit.  \n\n**Dictated by:** Dr. A. Smith, OB/GYN  \n**Date:** [Fictional]  \n*For testing purposes only—not real medical advice.*  \n\n---  \nThis fictional dictation includes intentional omissions and management gaps for testing/educational review. Always verify clinical details in real practice.\n\nGuideline:\n[ID] bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf\nTitle: BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.pdf\nContent: Antenatal corticosteroids given within seven days prior to preterm birth reduce perinatal and neonatal death and respiratory distress syndrome. For women undergoing planned caesarean birth between 37+0 and 38+6 weeks, an informed discussion should take place about the potential risks and benefits of corticosteroids. Corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated. Women with twins and triplets should also be offered corticosteroids. Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby. Antenatal corticosteroids should be offered to women with preterm prelabour rupture of membranes. Corticosteroids reduce neonatal death when given within 48 hours prior to birth, and benefits are still seen if given within 24 hours of birth.\n\nAntenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation. Steroids have short-term respiratory benefits for the neonate but may increase the risk of neonatal hypoglycemia. The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits. In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons. Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended. Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby. In pregnancies complicated by fetal growth restriction, pre-eclampsia, or antepartum hemorrhage, corticosteroids may be considered if imminent preterm birth is likely. Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.\n\nAntenatal corticosteroids should be offered to women with PPROM who are at increased risk of preterm birth. There is limited evidence to recommend repeat courses of antenatal corticosteroids if a woman remains at imminent risk of preterm birth seven days after administration. The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly. Antenatal corticosteroids are most effective when given within 48 hours prior to birth, with benefits seen within 24 hours of birth. They are most effective in reducing RDS in pregnancies that birth between 24 hours and 7 days of administration of the second dose.\n\nAntenatal corticosteroids have shown significant reductions in cases of RDS and cerebroventricular hemorrhage among infants born within specific time frames after administration. There is a reduction in fetal and neonatal death for births within 24 hours to seven days after administration. However, caution is advised in interpreting the data due to limitations in subgroup analyses. Population-based cohort studies support the early effects of antenatal corticosteroids, with the largest effect seen 24 hours to seven days after the first injection. Concerns about potential risks to both women and babies include effects on maternal blood glucose levels, fetal growth, neonatal hypoglycemia, long-term metabolic and neurological consequences, and potential impacts on brain development. WHO recommends offering antenatal corticosteroids only when minimum standards of maternal and neonatal hospital services are available.\n\nAntenatal corticosteroids should not be delayed in serious maternal or fetal conditions. In the presence of systemic infection, the use of corticosteroids should be carefully balanced due to the risk of exacerbating the infection. Repeat courses of corticosteroids may not reduce serious morbidity but can lead to smaller babies. The maximum number of corticosteroid courses in pregnancy should not exceed three. Research is needed to determine the effectiveness of corticosteroids in various conditions and to investigate potential off-target effects. Recommendations for future research include determining the effectiveness of corticosteroids in reducing neonatal morbidity in elective caesarean births at term and investigating the safety and effectiveness of steroids in multiple pregnancies and women with diabetes. Auditable topics include discussions about corticosteroids in planned caesarean births and the proportion of women offered corticosteroids for preterm birth. Support groups and useful links are provided for further information.\n\nAntenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. Managing hyperglycaemia during antenatal steroid administration, labour, and birth in pregnant women with diabetes. Should antenatal corticosteroids be considered in women with gestational diabetes before planned late gestation caesarean section. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Multiple courses of antenatal corticosteroid therapy in patients with preterm premature rupture of membranes. Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Length of latency with preterm premature rupture of membranes before 32 weeks' gestation. Duration of the latency period in preterm premature rupture of the membranes. Preterm premature rupture of the membranes. Length of latency with preterm premature rupture of membranes. Association of fetal growth restriction with neurocognitive function after repeated antenatal betamethasone treatment vs placebo. Antenatal corticosteroids for preterm premature rupture of membranes: single or repeat course. The clinical use of corticosteroids in pregnancy. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Maternal intramuscular dexamethasone versus betamethasone before preterm birth. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Antenatal dexamethasone for early preterm birth in low-resource countries. Antenatal corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence. Long-term impacts of prenatal synthetic glucocorticoids exposure on functional brain correlates of cognitive monitoring in adolescence. Prenatal betamethasone exposure and psychopathology risk in extremely low birth weight survivors in the third and fourth decades of life. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries.",
    "system_prompt": "You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.",
    "guideline_id": "bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf",
    "guideline_title": "BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.pdf"
  },
  "response": "Here is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations  \n1. **Different management plan** - Offer antenatal corticosteroids given the increased risk of preterm labor in twin gestation (24 weeks).  \n   Reason: The guideline states that corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated, including those with twins.  \n\n2. **Additional information needed** - Perform a cervical exam (length/dilation assessment) to evaluate preterm labor risk.  \n   Reason: The guideline emphasizes assessing imminent preterm birth risk, which requires cervical evaluation.  \n\n3. **Different management plan** - Refer to maternal-fetal medicine (MFM) for specialized twin pregnancy management.  \n   Reason: Twin pregnancies are high-risk and require MFM consultation for optimal monitoring and intervention planning.  \n\n### Somewhat Important Recommendations  \n1. **Improved patient advice** - Provide written materials on signs of preterm labor and corticosteroid benefits/risks.  \n   Reason: The guideline highlights the importance of informed discussions about corticosteroids, particularly in high-risk pregnancies.  \n\n2. **Additional information needed** - Inquire about urinary symptoms (e.g., dysuria, frequency) to rule out UTI as a cause of contractions.  \n   Reason: UTIs can trigger preterm labor; addressing this aligns with comprehensive preterm birth risk assessment.  \n\n3. **Different management plan** - Consider cervical length screening (transvaginal ultrasound) for preterm labor prediction.  \n   Reason: The guideline supports proactive monitoring in high-risk pregnancies to anticipate preterm birth.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Document fetal heart tones for both twins to confirm well-being.  \n   Reason: While not directly tied to corticosteroid use, fetal monitoring is critical in twin gestations.  \n\n2. **Improved patient advice** - Quantify nutritional recommendations (e.g., specific caloric/protein intake).  \n   Reason: Twin pregnancies require tailored nutritional guidance, though this is less urgent than preterm labor management.  \n\n### Unimportant Recommendations  \n1. **Additional information needed** - Document fundal height for growth tracking.  \n   Reason: Less critical than cervical assessment in this context, though useful for overall monitoring.  \n\n### Key Omissions in the Note:  \n- No discussion of corticosteroids despite twin gestation and preterm labor concerns.  \n- No contingency plan for worsening symptoms (e.g., when to administer corticosteroids or escalate care).  \n- No mention of maternal glucose monitoring if corticosteroids are given (relevant given family history of diabetes).  \n\n### Summary of Critical Actions:  \n1. Administer corticosteroids (e.g., dexamethasone 24 mg IM) given gestational age and twin pregnancy.  \n2. Refer to MFM and schedule cervical length screening.  \n3. Counsel patient on corticosteroid benefits/risks and preterm labor warning signs.  \n\nThese changes align the note with guideline priorities for reducing neonatal morbidity/mortality in preterm births.",
  "endpoint": "analyzeNoteAgainstGuideline",
  "timestamp": "2025-06-10T19-31-42",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\\n\\nFor each recommendation, specify:\\n1. The type of recommendation:\\n   - Additional information needed (history/examination/investigations)\\n   - Improved patient advice (options/statistics/patient information)\\n   - Different management plan\\n2. The specific recommendation\\n3. The reason for the recommendation (referencing the guideline)\\n\\nCategorize each recommendation by importance:\\n- Very Important: Critical for patient safety or guideline compliance\\n- Somewhat Important: Significant for optimal care but not critical\\n- Less Important: Would improve care but not essential\\n- Unimportant: Minor suggestions that could be considered\\n\\nFormat the response as follows:\\n\\n### Very Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Somewhat Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Less Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Unimportant Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\nClinical Note:\\n**Dictation: Clinical Interaction – Multiple Gestation (Fictional for Testing Purposes Only)**  \\n\\n**Patient Name:** Sarah Thompson  \\n**Age:** 32  \\n**Gestational Age:** 24 weeks  \\n**Gravidity/Parity:** G3 P1 (previous vaginal delivery at term)  \\n**Weight:** 68 kg  \\n**Last Menstrual Period:** Estimated based on early ultrasound  \\n**Chief Complaint:** \\\"I’ve been having more frequent Braxton Hicks contractions and some lower back pain.\\\"  \\n\\n### **History of Present Illness:**  \\nMs. Thompson is a 32-year-old woman with a dichorionic diamniotic twin pregnancy, confirmed by first-trimester ultrasound. She reports increased frequency of Braxton Hicks contractions over the past week, occurring 3–4 times per hour, non-painful but noticeable. She denies vaginal bleeding, fluid leakage, or decreased fetal movement. She notes intermittent lower back pain, which she attributes to prolonged standing at work. No recent travel or illness.  \\n\\n*Missing Pertinent Questions:*  \\n- No documented inquiry about urinary symptoms (possible UTI contributing to contractions).  \\n- No detailed dietary history (potential nutritional deficiencies in twin gestation).  \\n- No assessment of recent stressors or sleep disturbances.  \\n\\n### **Past Medical/Surgical History:**  \\n- Hypothyroidism (on levothyroxine, last TSH within normal range).  \\n- No prior gestational diabetes or hypertension.  \\n- No surgeries.  \\n\\n### **Medications:**  \\n- Prenatal vitamins  \\n- Levothyroxine 50 mcg daily  \\n\\n### **Family History:**  \\n- Mother with type 2 diabetes.  \\n- No known twin pregnancies in family.  \\n\\n### **Social History:**  \\n- Works full-time as a teacher.  \\n- No tobacco, alcohol, or recreational drug use.  \\n- Married, supportive partner.  \\n\\n### **Review of Systems:**  \\n- **Constitutional:** No fever, fatigue reported.  \\n- **Cardiovascular:** No palpitations or edema.  \\n- **Respiratory:** No shortness of breath.  \\n- **Gastrointestinal:** Occasional heartburn, no nausea/vomiting.  \\n- **Neurological:** No headaches or visual changes.  \\n\\n*Missing Pertinent Exam Findings:*  \\n- No fundal height measurement documented.  \\n- No cervical exam performed (to assess for shortening/dilation).  \\n- No documentation of fetal heart tones for both twins.  \\n\\n### **Assessment:**  \\n- **Multiple gestation (DCDA twins)** at 24 weeks with increased Braxton Hicks contractions.  \\n- Differential includes normal uterine irritability vs. preterm labor risk.  \\n- Back pain may be musculoskeletal but requires monitoring.  \\n\\n### **Plan:**  \\n1. **Activity Modification:** Advised reduced standing, pelvic rest, and hydration.  \\n2. **Contraction Monitoring:** Instructed to time contractions—if ≥6/hour or painful, present to labor and delivery.  \\n3. **Nutrition:** Emphasized increased protein/caloric intake (not quantified).  \\n4. **Follow-Up:** Scheduled for growth ultrasound in 2 weeks; no additional cervical length screening ordered.  \\n5. **Patient Counseling:** Discussed signs of preterm labor but did not provide written materials.  \\n\\n*Gaps in Management:*  \\n- No referral to maternal-fetal medicine despite twin gestation.  \\n- No discussion of antenatal corticosteroids for fetal lung maturity in case of preterm delivery.  \\n- No contingency plan if symptoms worsen before next visit.  \\n\\n**Dictated by:** Dr. A. Smith, OB/GYN  \\n**Date:** [Fictional]  \\n*For testing purposes only—not real medical advice.*  \\n\\n---  \\nThis fictional dictation includes intentional omissions and management gaps for testing/educational review. Always verify clinical details in real practice.\\n\\nGuideline:\\n[ID] bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf\\nTitle: BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.pdf\\nContent: Antenatal corticosteroids given within seven days prior to preterm birth reduce perinatal and neonatal death and respiratory distress syndrome. For women undergoing planned caesarean birth between 37+0 and 38+6 weeks, an informed discussion should take place about the potential risks and benefits of corticosteroids. Corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated. Women with twins and triplets should also be offered corticosteroids. Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby. Antenatal corticosteroids should be offered to women with preterm prelabour rupture of membranes. Corticosteroids reduce neonatal death when given within 48 hours prior to birth, and benefits are still seen if given within 24 hours of birth.\\n\\nAntenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation. Steroids have short-term respiratory benefits for the neonate but may increase the risk of neonatal hypoglycemia. The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits. In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons. Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended. Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby. In pregnancies complicated by fetal growth restriction, pre-eclampsia, or antepartum hemorrhage, corticosteroids may be considered if imminent preterm birth is likely. Women should be informed about the lack of evidence for the use of corticosteroids in small-for-gestational-age babies.\\n\\nAntenatal corticosteroids should be offered to women with PPROM who are at increased risk of preterm birth. There is limited evidence to recommend repeat courses of antenatal corticosteroids if a woman remains at imminent risk of preterm birth seven days after administration. The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly. Antenatal corticosteroids are most effective when given within 48 hours prior to birth, with benefits seen within 24 hours of birth. They are most effective in reducing RDS in pregnancies that birth between 24 hours and 7 days of administration of the second dose.\\n\\nAntenatal corticosteroids have shown significant reductions in cases of RDS and cerebroventricular hemorrhage among infants born within specific time frames after administration. There is a reduction in fetal and neonatal death for births within 24 hours to seven days after administration. However, caution is advised in interpreting the data due to limitations in subgroup analyses. Population-based cohort studies support the early effects of antenatal corticosteroids, with the largest effect seen 24 hours to seven days after the first injection. Concerns about potential risks to both women and babies include effects on maternal blood glucose levels, fetal growth, neonatal hypoglycemia, long-term metabolic and neurological consequences, and potential impacts on brain development. WHO recommends offering antenatal corticosteroids only when minimum standards of maternal and neonatal hospital services are available.\\n\\nAntenatal corticosteroids should not be delayed in serious maternal or fetal conditions. In the presence of systemic infection, the use of corticosteroids should be carefully balanced due to the risk of exacerbating the infection. Repeat courses of corticosteroids may not reduce serious morbidity but can lead to smaller babies. The maximum number of corticosteroid courses in pregnancy should not exceed three. Research is needed to determine the effectiveness of corticosteroids in various conditions and to investigate potential off-target effects. Recommendations for future research include determining the effectiveness of corticosteroids in reducing neonatal morbidity in elective caesarean births at term and investigating the safety and effectiveness of steroids in multiple pregnancies and women with diabetes. Auditable topics include discussions about corticosteroids in planned caesarean births and the proportion of women offered corticosteroids for preterm birth. Support groups and useful links are provided for further information.\\n\\nAntenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. Managing hyperglycaemia during antenatal steroid administration, labour, and birth in pregnant women with diabetes. Should antenatal corticosteroids be considered in women with gestational diabetes before planned late gestation caesarean section. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Multiple courses of antenatal corticosteroid therapy in patients with preterm premature rupture of membranes. Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Length of latency with preterm premature rupture of membranes before 32 weeks' gestation. Duration of the latency period in preterm premature rupture of the membranes. Preterm premature rupture of the membranes. Length of latency with preterm premature rupture of membranes. Association of fetal growth restriction with neurocognitive function after repeated antenatal betamethasone treatment vs placebo. Antenatal corticosteroids for preterm premature rupture of membranes: single or repeat course. The clinical use of corticosteroids in pregnancy. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Maternal intramuscular dexamethasone versus betamethasone before preterm birth. Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth. Antenatal dexamethasone for early preterm birth in low-resource countries. Antenatal corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence. Long-term impacts of prenatal synthetic glucocorticoids exposure on functional brain correlates of cognitive monitoring in adolescence. Prenatal betamethasone exposure and psychopathology risk in extremely low birth weight survivors in the third and fourth decades of life. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries.\",\n  \"system_prompt\": \"You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.\",\n  \"guideline_id\": \"bjog-2022-stock-antenatal-corticosteroids-to-reduce-neonatal-morbidity-and-mortality-pdf\",\n  \"guideline_title\": \"BJOG - 2022 - Stock - Antenatal corticosteroids to reduce neonatal morbidity and mortality.pdf\"\n}\n\nA: Here is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations  \n1. **Different management plan** - Offer antenatal corticosteroids given the increased risk of preterm labor in twin gestation (24 weeks).  \n   Reason: The guideline states that corticosteroids should be offered to women between 24+0 and 34+6 weeks' gestation in whom imminent preterm birth is anticipated, including those with twins.  \n\n2. **Additional information needed** - Perform a cervical exam (length/dilation assessment) to evaluate preterm labor risk.  \n   Reason: The guideline emphasizes assessing imminent preterm birth risk, which requires cervical evaluation.  \n\n3. **Different management plan** - Refer to maternal-fetal medicine (MFM) for specialized twin pregnancy management.  \n   Reason: Twin pregnancies are high-risk and require MFM consultation for optimal monitoring and intervention planning.  \n\n### Somewhat Important Recommendations  \n1. **Improved patient advice** - Provide written materials on signs of preterm labor and corticosteroid benefits/risks.  \n   Reason: The guideline highlights the importance of informed discussions about corticosteroids, particularly in high-risk pregnancies.  \n\n2. **Additional information needed** - Inquire about urinary symptoms (e.g., dysuria, frequency) to rule out UTI as a cause of contractions.  \n   Reason: UTIs can trigger preterm labor; addressing this aligns with comprehensive preterm birth risk assessment.  \n\n3. **Different management plan** - Consider cervical length screening (transvaginal ultrasound) for preterm labor prediction.  \n   Reason: The guideline supports proactive monitoring in high-risk pregnancies to anticipate preterm birth.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Document fetal heart tones for both twins to confirm well-being.  \n   Reason: While not directly tied to corticosteroid use, fetal monitoring is critical in twin gestations.  \n\n2. **Improved patient advice** - Quantify nutritional recommendations (e.g., specific caloric/protein intake).  \n   Reason: Twin pregnancies require tailored nutritional guidance, though this is less urgent than preterm labor management.  \n\n### Unimportant Recommendations  \n1. **Additional information needed** - Document fundal height for growth tracking.  \n   Reason: Less critical than cervical assessment in this context, though useful for overall monitoring.  \n\n### Key Omissions in the Note:  \n- No discussion of corticosteroids despite twin gestation and preterm labor concerns.  \n- No contingency plan for worsening symptoms (e.g., when to administer corticosteroids or escalate care).  \n- No mention of maternal glucose monitoring if corticosteroids are given (relevant given family history of diabetes).  \n\n### Summary of Critical Actions:  \n1. Administer corticosteroids (e.g., dexamethasone 24 mg IM) given gestational age and twin pregnancy.  \n2. Refer to MFM and schedule cervical length screening.  \n3. Counsel patient on corticosteroid benefits/risks and preterm labor warning signs.  \n\nThese changes align the note with guideline priorities for reducing neonatal morbidity/mortality in preterm births.\n\n--- Token Usage Report ---\nPrompt tokens: 2413\nCompletion tokens: 605\nTotal tokens: 3018\nEstimated cost: $0.001509",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 2413,
    "completion_tokens": 605,
    "total_tokens": 3018,
    "estimated_cost_usd": 0.001509
  }
}